CellCentric Limited hit key milestone

CellCentric Limited, the epigenetics company, hits funding milestone with new intellectual property agreements.

CellCentric Limited, the epigenetics company, has signed a series of new IP agreements with major institutions, including the prestigious University of Texas M. D. Anderson Cancer Center; to trigger the final tranche of funding from the Cambridge Enterprise Seed Funds.

Founded on an IP relationship with Prof Azim Surani at the University of Cambridge, CellCentric has managed to expand its discovery base to include a significant proportion of the world leading researchers and clinicians in this highly important space.

The company works through a hub and spoke network of interaction with its partner Principal Investigators. In collaboration with this network CellCentric is able to help identify and prioritise the best scientific opportunities for commercial development; specifically novel targets-ligands, functional screens and modulatory factors.

Epigenetics is a rapidly emerging field and intensive research in this area is set to provide innovative targets for drug discovery and novel approaches to therapeutics. Epigenetic approaches to cancer are already providing to have significant clinical value.